Review article · 2025 · Open access
Inflammation in cancer: therapeutic opportunities from new insights
Molecular Cancer, 24(1), 51 · Published 24 February 2025 · DOI 10.1186/s12943-025-02243-8
In brief
“Inflammation in cancer: therapeutic opportunities from new insights” is a 2025 review article by Yifei Xie and 7 co-authors, published in Molecular Cancer. OpenAlex counts 159 citations as of 15 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Molecular Cancer.
- Citations
- 159
- Most cited in
- 2026 (102)
- Field-weighted impact
- 15.17
- References
- 457
- Authors
- 8
Abstract
As one part of the innate immune response to external stimuli, chronic inflammation increases the risk of various cancers, and tumor-promoting inflammation is considered one of the enabling characteristics of cancer development. Recently, there has been growing evidence on the role of anti-inflammation therapy in cancer prevention and treatment. And researchers have already achieved several noteworthy outcomes. In the review, we explored the underlying mechanisms by which inflammation affects the occurrence and development of cancer. The pro- or anti-tumor effects of these inflammatory factors such as interleukin, interferon, chemokine, inflammasome, and extracellular matrix are discussed. Since FDA-approved anti-inflammation drugs like aspirin show obvious anti-tumor effects, these drugs have unique advantages due to their relatively fewer side effects with long-term use compared to chemotherapy drugs. The characteristics make them promising candidates for cancer chemoprevention. Overall, this review discusses the role of these inflammatory molecules in carcinogenesis of cancer and new inflammation molecules-directed therapeutic opportunities, ranging from cytokine inhibitors/agonists, inflammasome inhibitors, some inhibitors that have already been or are expected to be applied in clinical practice, as well as recent discoveries of the anti-tumor effect of non-steroidal anti-inflammatory drugs and steroidal anti-inflammatory drugs. The advantages and disadvantages of their application in cancer chemoprevention are also discussed.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Xie, Y., Liu, F., Wu, Y., Zhu, Y., Jiang, Y., Wu, Q., Dong, Z., & Liu, K. (2025). Inflammation in cancer: therapeutic opportunities from new insights. Molecular Cancer, 24(1), 51. https://doi.org/10.1186/s12943-025-02243-8
MLA 9
Xie, Yifei, et al. “Inflammation in cancer: therapeutic opportunities from new insights.” Molecular Cancer, vol. 24, no. 1, 2025, p. 51. https://doi.org/10.1186/s12943-025-02243-8.
Chicago
Xie, Yifei, Fangfang Liu, Yunfei Wu, Yuer Zhu, Yanan Jiang, Qiong Wu, Zigang Dong, and Kangdong Liu. 2025. “Inflammation in cancer: therapeutic opportunities from new insights.” Molecular Cancer 24 (1): 51. https://doi.org/10.1186/s12943-025-02243-8.
Harvard
Xie, Y. et al. (2025) ‘Inflammation in cancer: therapeutic opportunities from new insights’, Molecular Cancer, 24(1), p. 51. doi:10.1186/s12943-025-02243-8.
IEEE
Y. Xie et al., “Inflammation in cancer: therapeutic opportunities from new insights,” Molecular Cancer, vol. 24, no. 1, p. 51, 2025, doi: 10.1186/s12943-025-02243-8.
BibTeX
@article{xie2025inflammation,
title = {{Inflammation in cancer: therapeutic opportunities from new insights}},
author = {Xie, Yifei and Liu, Fangfang and Wu, Yunfei and Zhu, Yuer and Jiang, Yanan and Wu, Qiong and Dong, Zigang and Liu, Kangdong},
journal = {Molecular Cancer},
year = {2025},
volume = {24},
number = {1},
pages = {51},
doi = {10.1186/s12943-025-02243-8},
url = {https://doi.org/10.1186/s12943-025-02243-8}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- inflammation and cancer
- chronic inflammation
- tumor-promoting inflammation
- carcinogenesis
- anti-inflammatory therapy
- chemoprevention
- interleukins
- interferon
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Xie, Y., Liu, F., Wu, Y., Zhu, Y., Jiang, Y., Wu, Q., Dong, Z., & Liu, K. (2025). Inflammation in cancer: therapeutic opportunities from new insights. Molecular Cancer, 24(1), 51. https://doi.org/10.1186/s12943-025-02243-8
How many times has this paper been cited?
159 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Molecular Cancer.
Who wrote this paper?
Yifei Xie, Fangfang Liu, Yunfei Wu, Yuer Zhu, Yanan Jiang, Qiong Wu, Zigang Dong, Kangdong Liu.
What is the DOI of this paper?
10.1186/s12943-025-02243-8. The permanent link is https://doi.org/10.1186/s12943-025-02243-8.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.